Madhavan Balachandran Sells 11,685 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Madhavan Balachandran sold 11,685 shares of uniQure stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the sale, the director directly owned 43,254 shares in the company, valued at $1,949,025.24. This trade represents a 21.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madhavan Balachandran also recently made the following trade(s):

• On Monday, June 15th, Madhavan Balachandran sold 10,000 shares of uniQure stock. The shares were sold at an average price of $27.85, for a total value of $278,500.00.
• On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total value of $53,930.58.

uniQure Stock Performance

Shares of QURE stock opened at $49.04 on Wednesday. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -14.09 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is $25.97 and its 200-day moving average price is $22.47. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Equities research analysts forecast that uniQure N.V. will post -3.64 EPS for the current year.

Analysts Set New Price Targets

QURE has been the topic of a number of recent research reports. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $15.00 to $60.00 in a report on Monday, March 9th. The Goldman Sachs Group increased their price objective on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 18th. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.92.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported promising early results from its AMT-260 epilepsy program, with initial patients showing large seizure reductions and no treatment-related serious adverse events, supporting confidence in the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Several news outlets highlighted early AMT-260 data showing seizure reductions of 79% to 100% in three patients, which is helping fuel investor enthusiasm for the stock. Article Title
• Positive Sentiment: Analysts remain bullish on QURE, with recent upgrades and higher price targets reinforcing the view that the latest pipeline progress could create additional upside. Article Title
• Neutral Sentiment: The company also announced preliminary Phase I/IIa data for AMT-260, which is an important but expected clinical milestone for a development-stage biotech. Article Title
• Negative Sentiment: uniQure launched a proposed $150 million public offering, plus a potential $22.5 million greenshoe, which could dilute existing shareholders even as it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may weigh on sentiment, even though the trades were made under pre-arranged 10b5-1 plans. Article Title

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC bought a new stake in uniQure during the 3rd quarter worth approximately $50,000. Torren Management LLC purchased a new stake in shares of uniQure in the fourth quarter worth approximately $28,000. FNY Investment Advisers LLC lifted its holdings in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares in the last quarter. Finally, IFP Advisors Inc purchased a new position in shares of uniQure during the fourth quarter valued at approximately $48,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.